# Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer

> **NCT00540943** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 25 (actual)

## Conditions studied

- Neoplasms, Colorectal

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Cetuximab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00540943
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-13
- **Primary completion:** 2010-05-03
- **Final completion:** 2010-05-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540943, "Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00540943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*